
































Who Did the Arthroplasty? Hip Fracture Surgery
ReoperationRates areNotAffectedbyTypeof Training—An
Analysis of the HEALTH Database
Ryan D. DeAngelis, MD,a Gregory T. Minutillo, MD, MPH,a Matthew K. Stein, MD,a
Emil H. Schemitsch, MD, FRCSC,b Sofia Bzovsky, MSc,c Sheila Sprague, PhD,c,d
Mohit Bhandari, MD, PhD, FRCSC,c,d Derek J. Donegan, MD, MBA,a and Samir Mehta, MDa on behalf of
the HEALTH Investigators
Objectives: This study compares outcomes for patients with
displaced femoral neck fractures undergoing hemiarthroplasty
(HA) or total hip arthroplasty (THA) by surgeons of different
fellowship training.
Design: Retrospective review of HEALTH trial data.
Setting: Eighty clinical sites across 10 countries.
Patients/Participants: One thousand four hundred forty-one
patients $50 years with low-energy hip fractures requiring surgical
intervention.
Intervention: Patients were randomized to either HA or
THA groups in the initial data set. Surgeons’ fellowship
training was ascertained retrospectively, and outcomes were
compared.
Main Outcome Measurements: The main outcome was an
unplanned secondary procedure at 24 months. Secondary outcomes
included death, serious adverse events, prosthetic joint infection
(PJI), dislocation, discharge disposition, and use of ambulatory
devices postoperatively.
Results: There was a significantly higher risk of PJI in patients
treated by surgeons without fellowship training in arthroplasty (P =
0.01), surgeons with unknown fellowship training (P = 0.03), and
surgeons with no fellowship training (P = 0.02) than those treated by
an arthroplasty-trained surgeon. There were significantly higher odds
of being discharged to a facility rather than home in patients who
underwent surgery by a surgeon with no fellowship training com-
pared with arthroplasty–fellowship-trained surgeons (P = 0.03).
Conclusions: Arthroplasty for hip fracture can be performed by all
orthopaedic surgeons with equivalent reoperation rates. Infection
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prevention strategies and use of “care pathways” by arthroplasty-
fellowship-trained surgeons may account for the lower risk of PJI
and higher rate of discharge to home. The authors advocate for the
use of evidence-based infection prevention initiatives and standard-
ized care pathways in this patient population.
Key Words: displaced femoral neck fracture, total hip arthroplasty,
hemiarthroplasty, fellowship training
Level of Evidence: Prognostic Level II. See Instructions for
Authors for a complete description of levels of evidence.
(J Orthop Trauma 2020;34:S64–S69)
INTRODUCTION
Femoral neck fractures are common injuries in the
geriatric population, with an annual incidence projected to
surpass 6.26 million worldwide by 2050.1 This increasing
incidence underscores the necessity for treatment strategies
that optimize patient outcomes from a surgical and medical
perspective. Despite the overall success in the current treat-
ment of femoral neck fractures, devastating complications
persist. These complications include, but are not limited to,
thromboembolic events, infection, implant failures prompting
revision surgery, and one-year mortality of approximately
30%.2–5
Nondisplaced femoral neck fractures are amenable to
closed reduction and percutaneous pinning, but displaced
fractures are typically treated with either hemiarthroplasty
(HA) or total hip arthroplasty (THA). The decision to perform
a HA or THA is driven by several factors, such as previous
hip pain, activity level, risk for dislocation, and surgeon
comfort or training. Although most displaced femoral neck
fractures are still treated with HA, current studies have
demonstrated an increasing trend and a potentially improved
outcome in THAs.6–9
The field of orthopaedics has become progressively
more subspecialized over time with .90% of the US ortho-
paedic residency graduates completing a fellowship as of
2013.10,11 Recent literature has studied femoral neck fractures
undergoing HA and compared outcomes based on surgeon
fellowship training: arthroplasty, trauma, or general orthopae-
dics.12 The data show decreased operative time with arthro-
plasty surgeons, higher complication rates with general
orthopaedists, and higher mortality rates with trauma sur-
geons. However, this was a single-center series that included
only 298 hip fractures.
The Hip Fracture Evaluation with Alternatives of THA
versus Hemiarthroplasty (HEALTH) trial found no difference
in outcomes in HA versus THA for femoral neck fractures at
2-year follow-up.13 This prospective randomized multicenter
study included patients undergoing HA and THA performed
by surgeons with various training backgrounds. There are no
studies examining the HEALTH data outcomes of patients
treated by fellowship-trained orthopaedic surgeons versus
those treated by non–fellowship-trained orthopaedic sur-
geons. This study serves to investigate a potential difference
in outcomes for HA or THA after femoral neck fractures
treated by fellowship-trained orthopaedic surgeons and non–
fellowship-trained orthopaedic surgeons. Our hypothesis is
that there is no difference in outcomes at 2 years for HA or
THA after femoral neck fractures based on fellowship
training.
METHODS
Our study was a retrospective review of the data from
the HEALTH trial.
Both the primary surgeon and supporting institution
were listed for every case in the database. Several resources
were used to identify each surgeon’s subspecialty training.
The surgeon’s profile on their hospital web site was the pri-
mary source of information. Several surgeons were contacted
directly through telephone and/or e-mail, when their informa-
tion could not be found otherwise. Professional networking
web sites, such as LinkedIn and Doximity, were used as well.
The surgeons’ level of training was classified in to 5
major groups as follows: trauma-fellowship trained,
arthroplasty-fellowship trained, fellowship training outside
of trauma or arthroplasty, unknown fellowship status, or no
fellowship training. Fellowship was defined as subspecialized
training completed after completion of an orthopaedic surgery
residency. If a surgeon had completed individual fellowships
in both trauma and arthroplasty or a combination fellowship
focusing on trauma and arthroplasty, that surgeon was
counted toward the arthroplasty group because the interven-
tion in the HEALTH trial was arthroplasty. Surgeons for
whom there was no available information regarding their
training were included in the unknown fellowship group. A
surgeon was only listed as having no fellowship if their train-
ing record clearly stated their residency training and did not
identify a fellowship.
Participant demographics, baseline characteristics,
major comorbidities, and outcomes of the population were
summarized by fellowship training and treatment group.
Descriptive statistics were used to summarize these data.
Means and SDs were used for continuous data, and categor-
ical data were presented as frequencies and percentages.
Cox regression analyses were then performed to
investigate the association between fellowship training and
5 HEALTH data outcomes in all participants, using fellow-
ship training as the independent variable in each model. We
also included randomized treatment as a covariate and
surgeon as a random effect in each model. We used the
following outcomes as the dependent variable in each
respective model: (1) the HEALTH trial primary outcome
of unplanned secondary hip procedures within 24 months of
initial surgery (yes vs. no), (2) hip dislocation (yes vs. no), (3)
death (yes vs. no), (4) serious adverse events (yes vs. no), and
(5) prosthetic joint infection (PJI) (yes vs. no). We also
performed the 5 abovementioned analyses including only
participants in the THA group and only participants in the HA
group, separately. Randomized treatment was removed as a
covariate when we performed analyses on the separate
treatment groups. Results were reported as hazard ratios
(HRs) with 95% confidence intervals (CIs). T tests were 2-
tailed with alpha = 0.05.
We also performed 2 logistic regression analyses to
investigate the association between fellowship training and 2
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HEALTH data outcomes in all participants, using fellowship
training as the independent variable in each model. We also
included randomized treatment as a covariate and surgeon as
a random effect in each model. We used the following
outcomes as the dependent variable in each respective model:
1) discharge disposition (discharged to a facility vs. dis-
charged home) and 2) use of ambulatory devices postoper-
atively (use of an ambulatory device vs. nonuse of an
ambulatory device). Prefracture living status and prefracture
functional status were also included as covariates in these 2
models, respectively. We also performed the 2 abovemen-
tioned logistic regression analyses including only patients in
the THA group and only patients in the HA group, separately.
Randomized treatment was removed as a covariate when we
performed analyses on the separate treatment groups. Results
were reported as odds ratios (ORs) with 95% CIs. T tests were
2-tailed with alpha = 0.05.
All data analyses were conducted using R (version
4.0.0, R Foundation for Statistical Computing, Vienna,
Austria).
RESULTS
The HEALTH trial enrolled 1441 patients with 723
patients randomized to HA and 718 patients randomized to
THA. Of these 1441 procedures, 281 cases were performed
by orthopaedic surgeons who completed a fellowship in
orthopaedic trauma, 394 cases were performed by orthopae-
dic surgeons who completed a fellowship in arthroplasty, and
139 cases were performed by orthopaedic surgeons who
completed fellowship in specialties other than trauma or
arthroplasty. There were 308 cases completed by orthopaedic
surgeons who did not complete any further training after their
residency and 319 cases completed by orthopaedic surgeons
whose fellowship training status was unknown. Both HA and
THA cases were performed by each training group. There was
no difference in the body mass index, prefracture living
setting, prefracture functional status, American Society of
Anesthesiologists (ASA) score, or major comorbidities when
the patients were grouped by surgical training (P . 0.05 for
all). There were differences among the groups about age, sex,
and ethnicity (P , 0.05 for all). These demographic data are
detailed in Supplemental Digital Content 1 (Appendix 1,
http://links.lww.com/JOT/B210).
There was no difference in the incidence of unplanned
secondary procedure, dislocation, death, or serious adverse
events among the different groups (P . 0.05 for all). When
analyzing the HA and THA patients separately, there was still
no difference in these end points (P . 0.05 for all) between
the fellowship training groups.
There was a difference in PJI among the fellowship
training groups (P = 0.02). The patients treated by surgeons
who completed fellowships outside of trauma or arthroplasty
(HR 4.06, 95% CI 1.46–11.33; P = 0.01), surgeons with
unknown fellowship training (HR 3.69, 95% CI 1.11–
12.27; P = 0.03), and surgeons with no fellowship training
(HR 3.42, 95% CI 1.20–9.74; P = 0.02) had a higher risk of
PJI than those treated by an arthroplasty-trained surgeon.
When looking specifically at the THA patients, there was a
higher risk of PJI in the no fellowship group as compared to
the arthroplasty-trained group (HR 4.49, 95%, CI 1.20–16.81;
P = 0.03). In the HA patients, there was no difference in PJI
among the various fellowship groups (P . 0.05).
There were significantly higher odds of being dis-
charged to a facility rather than home postoperatively for the
patients who underwent surgery with a surgeon with no
fellowship training (OR 1.43, 95% CI 1.02–1.99; P = 0.03) as
compared to undergoing surgery with an arthroplasty–
fellowship-trained surgeon. This difference was not demon-
strated when looking at HA and THA groups separately (P .
0.05 for all). There was no difference in the use of assistive
devices postoperatively, when comparing the fellowship
training groups (P . 0.05 for all). These results are sum-
marized in Tables 1–3.
DISCUSSION
We found no difference relative to surgical training
when comparing the risk of unplanned secondary procedure,
dislocation, death, and serious adverse events for patients
who underwent HA or THA for displaced femoral neck
fractures. However, there was a significantly higher risk of
PJI in patients treated by surgeons who completed fellow-
ships outside of arthroplasty, surgeons with unknown fellow-
ship training, and surgeons with no fellowship training than
those treated by an arthroplasty-trained surgeon. Specifically,
in the THA group, being treated by a surgeon with no
fellowship training was associated with a higher risk of PJI as
compared to those treated by an arthroplasty-trained surgeon.
Previous literature has suggested a difference in
numerous outcomes related to surgical training; our data did
not support this. Mabry et al reviewed 298 displaced femoral
neck fractures treated with HA and studied outcomes
comparing surgeons trained in arthroplasty, trauma, or no
fellowship (“generalists”). Their series demonstrated that
arthroplasty-trained surgeons had the shortest operative time,
generalists had the highest overall complication rate, and
trauma-trained surgeons had the highest mortality rate at
one year.12 In addition, there was no difference in PJI in their
study. Our study also showed no difference in PJI for patients
undergoing HA for hip fracture. However, there was a signif-
icantly higher risk of PJI in the THA patients (Table 3).
Considering there was no overall difference in reoperation
rates among groups, PJIs in the THA patients were not caus-
ing a significant rate of return to the operating room, and thus,
the clinical implications of this finding in our study are uncer-
tain. Given this finding, it would be rather drastic to recom-
mend that THA for hip fracture be avoided by surgeons with
no fellowship training. Instead, our group recommends all
surgeons performing these procedures follow the most current
infection prevention guidelines.
There were several limitations in the Mabry et al study
as it was a single-center series of only 298 patients with 35
surgeons performing only hip HA. The HEALTH trial
included nearly 5 times the number of patients in 80 centers
across 10 countries undergoing both HA and THA.13 With a
much larger and more diverse study group of both patients
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and surgeons, our results are more generalizable to the entire
population.
Although there is an overall scarcity of literature
focusing specifically on fellowship training and correlation
with surgical outcomes in the treatment of hip fractures, there
have been numerous studies examining outcomes about
surgeon volume. Ames et al compared HA for hip fracture
outcomes in surgeons in relation to their yearly volume. The
study team divided the surgeons ranging from no volume (0
cases/year) to high volume (25+ cases/year).14 When compar-
ing no volume with high volume, this group found that the
high-volume group had significantly lower rates of mortality,
dislocation, and superficial infection. Revision surgery rates
were significantly higher for the high-volume surgeons com-
pared with no-volume surgeons; however, this may simply be
due to the fact that the high-volume surgeons were more
comfortable in performing revision surgeries. Nonetheless,
these findings were likely not observed in our study due to
the fact that more than 95% of the surgeons who participated
in the HEALTH trial met the threshold for surgical exper-
tise.13,15 Very few, if any, of the HEALTH trial surgeons
are low-volume surgeons in regard to arthroplasty.
TABLE 1. Association Between Fellowship Training and
HEALTH Outcomes in all Arthroplasty Patients
Outcome HR (95% CI) P
Unplanned secondary procedure Overall: 0.82
Trauma vs. arthroplasty 1.11 (0.64–1.95)
Other vs. arthroplasty 1.35 (0.80–2.26)
Unknown vs. arthroplasty 1.34 (0.70–2.57)
None vs. arthroplasty 0.81 (0.45–1.46)
Dislocation Overall: 0.66
Trauma vs. arthroplasty 0.88 (0.38–2.04)
Other vs. arthroplasty 1.02 (0.47–2.22)
Unknown vs. arthroplasty 0.76 (0.25–2.32)
None vs. arthroplasty 0.82 (0.37–1.82)
Death Overall: 0.85
Trauma vs. arthroplasty 1.14 (0.74–1.75)
Other vs. arthroplasty 1.24 (0.83–1.86)
Unknown vs. arthroplasty 1.15 (0.68–1.97)
None vs. arthroplasty 1.14 (0.75–1.73)
Serious adverse event Overall: 0.18
Trauma vs. arthroplasty 1.02 (0.80–1.31)
Other vs. arthroplasty 1.02 (0.80–1.30)
Unknown vs. arthroplasty 1.18 (0.87–1.60)
None vs. arthroplasty 0.98 (0.77–1.26)
Prosthetic joint infection Overall: 0.02
Trauma vs. arthroplasty 3.77 (0.91–8.37) 0.07
Other vs. arthroplasty 4.06 (1.46–11.33) 0.01
Unknown vs. arthroplasty 3.69 (1.11–12.27) 0.03
None vs. arthroplasty 3.42 (1.20–9.74) 0.02
OR (95% CI) P
Discharged to facility postoperatively Overall: 0.04
Trauma vs. arthroplasty 1.34 (0.96–1.88) 0.09
Other vs. arthroplasty 1.26 (0.91–1.74) 0.17
Unknown vs. arthroplasty 1.46 (0.95–2.24) 0.08
None vs. arthroplasty 1.43 (1.02–1.99) 0.03
Use of ambulatory devices
postoperatively
Overall: 0.11
Trauma vs. arthroplasty 0.45 (0.04–5.05)
Other vs. arthroplasty 0.90 (0.01–9.01)
Unknown vs. arthroplasty 0.48 (0.03–7.95)
None vs. arthroplasty 0.19 (0.02–1.63)
Other, fellowship not in trauma or arthroplasty; Unknown, unknown fellowship
status; None, no fellowship training.
Significance = P , 0.05.
CI, confidence interval; HR, hazard ratio; OR, odds ratio.
TABLE 2. Association Between Fellowship Training and
HEALTH Outcomes in HA Patients
Outcome HR (95% CI) P
Unplanned secondary procedure Overall: 0.14
Trauma vs. arthroplasty 0.78 (0.36–1.65)
Other vs. arthroplasty 1.39 (0.63–3.08)
Unknown vs. arthroplasty 0.91 (0.45–1.84)
None vs. arthroplasty 0.34 (0.12–0.95)
Dislocation Overall: 0.54
Trauma vs. arthroplasty 0.50 (0.12–2.01)
Other vs. arthroplasty 0.66 (0.13–3.44)
Unknown vs. arthroplasty 0.60 (0.16–2.24)
None vs. arthroplasty 0.58 (0.13–2.52)
Death Overall: 0.15
Trauma vs. arthroplasty 1.39 (0.69–2.77)
Other vs. arthroplasty 2.12 (0.99–4.54)
Unknown vs. arthroplasty 1.85 (0.97–3.54)
None vs. arthroplasty 1.49 (0.71–3.15)
Serious adverse event Overall: 0.39
Trauma vs. arthroplasty 0.87 (0.67–1.39)
Other vs. arthroplasty 1.31 (0.86–2.00)
Unknown vs. arthroplasty 0.90 (0.63–1.29)
None vs. arthroplasty 0.86 (0.57–1.28)
Prosthetic joint infection Overall: 0.20
Trauma vs. arthroplasty 1.69 (0.31–9.26)
Other vs. arthroplasty 2.57 (0.42–15.52)
Unknown vs. arthroplasty 3.48 (0.75–16.14)
None vs. arthroplasty 2.03 (0.36–11.37)
OR (95% CI) P
Discharged to facility postoperatively Overall: 0.15
Trauma vs. arthroplasty 1.49 (0.92–2.39)
Other vs. arthroplasty 2.21 (1.21–4.03)
Unknown vs. arthroplasty 1.57 (0.98–2.52)
None vs. arthroplasty 1.47 (0.89–2.44)
Use of ambulatory devices
postoperatively
Overall: 0.73
Trauma vs. arthroplasty 1.22 (0.07–19.92)
Other vs. arthroplasty 0.72 (0.04–11.79)
Unknown vs. arthroplasty 0.91 (0.01–13.09)
None vs. arthroplasty 0.57 (0.06–5.79)
Other, fellowship not in trauma or arthroplasty; Unknown, unknown fellowship
status; None, no fellowship training.
Significance = P , 0.05.
CI, confidence interval; HR, hazard ratio; OR, odds ratio.
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Another difference noted in our study was a higher
odds of discharge to a facility rather than home postopera-
tively for cases performed by nonarthroplasty–fellowship-
trained surgeons. This finding may be explained by the
utilization of standardized “care pathways” by arthroplasty-
trained surgeons with their hip fracture patients. Many
arthroplasty surgeons use these evidence-based algorithms for
their elective arthroplasty cases to optimize patient care and
ultimately improve outcomes and reduce cost.16–19 Previous
studies have substantiated the implementation of these path-
ways because they significantly decrease both cost and length
of stay.20 In addition, the data show that these pathways lead
to a higher rate of discharge to home.21 Arthroplasty surgeons
using their “care pathways” despite these cases not being a
part of their elective practice may explain this group’s higher
rate of discharge to home postoperatively. Given the data
supporting the use of these pathways for elective joint arthro-
plasty patients, the authors advocate for utilization of these
pathways in hip fracture patients as well.
There are several limitations to this study. Given that
the HEALTH trial was international, there were numerous
surgeons where details regarding surgical training were
particularly difficult to ascertain. This was challenging for
some of the surgeons in Europe, partially because of a
language barrier and a lack of hospital web sites clearly
displaying the surgeon’s training history. This created a large
“unknown fellowship” group that may have included sur-
geons with subspecialized training. In addition, the surgeons
labeled as “no fellowship” may be somewhat misleading and
imply that these surgeons are not specialized in one area or
lack expertise. In this study, completion of fellowship was
used as an objective marker of “expertise” in a specific sub-
specialty. Regardless of completing a fellowship, many ortho-
paedic surgeons focus on specific areas of practice. Some
more senior surgeons did not complete a fellowship because
fellowship training was not as common as it is today; these
surgeons are still “experts” in their field. As such, this may
have skewed the data because some surgeons may have been
“misrepresented” if their training information could be not
obtained or if they did not complete a fellowship.
Our study supports that arthroplasty for hip fracture can
be performed by all orthopaedic surgeons with no difference
in reoperation rates at 2 years. The authors advocate for the
utilization of the most current infection prevention strategies
and standardized care pathways when treating these patients.
The surgeons performing these procedures, regardless of
fellowship training, should remain up-to-date on the current
operative and postoperative recommendations in caring for
these patients.
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